GlycoMimetics’ (GLYC) “Neutral” Rating Reaffirmed at HC Wainwright

GlycoMimetics (NASDAQ:GLYC)‘s stock had its “neutral” rating reiterated by investment analysts at HC Wainwright in a research report issued on Monday, Benzinga reports.

Several other research analysts also recently issued reports on the stock. StockNews.com downgraded shares of GlycoMimetics from a “hold” rating to a “sell” rating in a research report on Thursday, March 14th. Capital One Financial reaffirmed an “overweight” rating on shares of GlycoMimetics in a report on Thursday, February 22nd.

GlycoMimetics Stock Down 81.0 %

GLYC stock traded down $1.48 during midday trading on Monday, hitting $0.35. The company’s stock had a trading volume of 33,911,671 shares, compared to its average volume of 865,782. GlycoMimetics has a 52-week low of $0.34 and a 52-week high of $3.53. The firm has a market capitalization of $22.40 million, a P/E ratio of -0.61 and a beta of 2.30. The firm has a 50-day simple moving average of $2.53 and a 200-day simple moving average of $2.35.

GlycoMimetics (NASDAQ:GLYC) last announced its quarterly earnings results on Wednesday, March 27th. The biotechnology company reported ($0.14) EPS for the quarter, topping the consensus estimate of ($0.15) by $0.01. The company had revenue of $0.01 million for the quarter. On average, sell-side analysts expect that GlycoMimetics will post -0.54 earnings per share for the current fiscal year.

Institutional Trading of GlycoMimetics

Hedge funds and other institutional investors have recently made changes to their positions in the company. Advisor OS LLC purchased a new stake in GlycoMimetics during the fourth quarter worth about $238,000. MJP Associates Inc. ADV purchased a new stake in GlycoMimetics during the fourth quarter worth about $238,000. Finally, Acuta Capital Partners LLC purchased a new stake in GlycoMimetics during the third quarter worth about $41,000. Hedge funds and other institutional investors own 75.19% of the company’s stock.

GlycoMimetics Company Profile

GlycoMimetics, Inc, a clinical-stage biotechnology company, focuses on the discovery and development of glycobiology-based therapies for cancers, including acute myeloid leukemia (AML) and inflammatory diseases with unmet needs in the United States. It is developing uproleselan, an E-selectin antagonist, which is used in combination with chemotherapy to treat AML, as well as in phase 3 trial to treat relapsed/refractory AML.